EU Proposes MDR Annex II Update for IVD Hardware Biocompatibility

The European Commission has proposed an amendment to Annex II of Regulation (EU) 2017/745 (MDR), requiring long-term aged biocompatibility data for in vitro diagnostic hardware — a development with direct implications for IVD hardware manufacturers, exporters, and technical documentation providers, especially those based in China.

Event Overview

On 24 April 2026, the European Commission published the Proposal for Amending Regulation (EU) 2017/745 Annex II. The proposal mandates that all in vitro diagnostic (IVD) hardware devices include, in their CE technical documentation, a biocompatibility retest report conducted on materials subjected to ≥24 months of simulated aging conditions — in addition to standard ISO 10993 testing. The amendment is currently under review and, if adopted in Q3 2026, would introduce new compliance requirements for CE marking submissions.

Which Sub-Sectors Are Affected

Direct Exporters of IVD Hardware

Exporters submitting CE technical files for IVD hardware will face mandatory inclusion of aged biocompatibility reports. This affects submission timelines and validation readiness: each model will require an additional 6–8 weeks for aging and retesting, plus approximately €12,000 in per-model test costs.

Manufacturers & Contract Manufacturers

Companies responsible for design, material selection, or final assembly of IVD hardware must now assess whether current material specifications and supplier declarations support ≥24-month aging stability. Existing device designs may require material requalification or reformulation if aging alters surface chemistry or extractables profile.

Testing Laboratories & Regulatory Support Providers

Labs offering ISO 10993 services will need to validate and document aging protocols aligned with the proposed Annex II criteria. Regulatory consultants supporting CE submissions must update technical file templates and client guidance to incorporate aged biocompatibility evidence as a distinct deliverable.

Supply Chain & Material Suppliers

Suppliers of polymers, adhesives, coatings, or housing components used in IVD hardware may receive new material qualification requests from OEMs — including accelerated aging data packages, batch-specific stability statements, and compatibility records across multiple aging durations.

What Relevant Enterprises or Practitioners Should Focus On — And How to Respond Now

Monitor Official Adoption Timeline and Scope Clarifications

Track updates from the European Commission, MDCG, and notified bodies regarding the formal adoption date, transitional provisions, and whether the requirement applies retroactively to already-certified devices or only to new submissions post-implementation.

Identify High-Risk Device Categories Early

Focus initial assessment on IVD hardware with prolonged patient-contact components (e.g., sample collection tubes, cartridge housings, fluidic manifolds) or materials known for hydrolytic/oxidative degradation (e.g., certain polyesters, polyurethanes, silicones) — these are most likely to require retesting.

Distinguish Between Policy Signal and Enforceable Requirement

As this remains a proposal — not yet law — avoid premature full-scale revalidation. Instead, initiate internal gap assessments: map current material specifications against potential aging endpoints (e.g., cytotoxicity, sensitization, genotoxicity after aging), and verify whether existing supplier data covers ≥24-month conditions.

Prepare Documentation and Supplier Engagement Protocols

Update internal technical documentation workflows to flag aging-related biocompatibility evidence as a discrete module. Begin engaging key material suppliers now to request aging data availability statements — not full reports — to inform feasibility planning ahead of formal implementation.

Editorial Perspective / Industry Observation

From industry perspective, this proposal signals a tightening of biological safety expectations for IVD hardware — shifting focus from initial biocompatibility to performance stability over time. Analysis来看, it reflects growing regulatory attention to real-world material degradation pathways, particularly where devices may be stored or reused beyond typical shelf-life assumptions. Observation来看, the timing aligns with broader EU efforts to harmonize IVD and general medical device safety expectations under MDR, though the scope remains limited to hardware (not reagents or software). Current more appropriate interpretation is that this is a policy signal — not yet an operational mandate — but one that warrants structured preparation given its likely adoption and narrow window for technical adaptation.

This development does not revise fundamental biocompatibility principles, but rather extends their temporal dimension. It underscores that regulatory compliance for IVD hardware is increasingly defined by lifecycle-aware evidence — not just point-in-time test results.

Information Source: European Commission Proposal COM(2026) 245 final, published 24 April 2026. Note: Formal adoption status, transitional arrangements, and detailed aging protocol requirements remain pending and subject to ongoing consultation.